EXCLUSIVE: BioRestorative Therapies Adds Additional Sites For Lumbar Disc Disease Trial

BioRestorative Therapies Inc BRTX has entered into agreements with Vantage Clinical Trials LLC for its Phase 2 trial targeting chronic lumbar disc disease (cLDD). 

Vantage Clinical Trials LLC is located in Florida and brings three separate clinical sites to BioRestortive’s Phase 2 trial.

BioRestorative’s Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of its autologous investigational stem cell-based therapeutic, BRTX-100. 

Related: EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study.

99 eligible patients will be randomized at up to 15 sites in the U.S. to receive either BRTX-100 or control.

“With the execution of the Vantage agreements, we are bringing on board three additional sites with a well-established history of conducting clinical research,” said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. 

“Adding high-profile sites is our top priority as we ramp up enrollment for our clinical trial targeting cLDD,” he added.

Price Action: BRTX shares closed at $3.10 on Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMarket-Moving ExclusivesExclusivesGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!